Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer

Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer

Abstract Background HER2-overexpressing metastatic breast cancers are challenging practice in oncology when they become resistant to anti-HER2 therapies such as trastuzumab. In these clinical situations, HER2-overexpression persists in metastatic localizations, and can thus be used for active target...

Full description

Bibliographic Details
Main Authors:	Toni Nunes, Thomas Pons, Xue Hou, Khanh Van Do, Benoît Caron, Marthe Rigal, Mélanie Di Benedetto, Bruno Palpant, Christophe Leboeuf, Anne Janin, Guilhem Bousquet
Format:	Article
Language:	English
Published:	BMC 2019-07-01
Series:	Journal of Experimental & Clinical Cancer Research
Subjects:	Functionalized gold nanoparticles HER2-overexpressing breast cancer Trastuzumab resistance Resistance reversion Photothermal therapy Femtosecond laser
Online Access:	http://link.springer.com/article/10.1186/s13046-019-1305-x

Similar Items

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

Trastuzumab: More Than a Guide in HER2-Positive Cancer Nanomedicine
by: Celia Nieto, et al.
Published: (2020-08-01)

Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
by: Adamczyk A, et al.
Published: (2018-08-01)

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
by: Tameka A Bailey, et al.
Published: (2011-01-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
by: Sònia Palomeras, et al.
Published: (2019-07-01)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
by: Brenen P. Swofford, et al.
Published: (2017-12-01)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
by: Swofford, Brenen P., et al.
Published: (2017)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
by: Xin Li, et al.
Published: (2018-08-01)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
by: Silvia Pelligra, et al.
Published: (2020-05-01)

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
by: Darryl P. Leong, MBBS, MPH, MBiostat, PhD, et al.
Published: (2019-09-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer
by: Sachin S Hingmire, et al.
Published: (2017-01-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
by: Paul Stewart, et al.
Published: (2020-12-01)

Risk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases
by: Joanna Huszno, et al.
Published: (2015-09-01)

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
by: E. V. Lubennikova, et al.
Published: (2017-11-01)

Trastuzumab administration during pregnancy: un update
by: Angeliki Andrikopoulou, et al.
Published: (2021-04-01)

Correlation between resistance to trastuzumab and miR-141 relative expression in the BT-474 human breast cancer cell line
by: Zohreh Rezaei, et al.
Published: (2017-10-01)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01)

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
by: L G Zhukova, et al.
Published: (2018-06-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Trastuzumab: updated mechanisms of action and resistance in breast cancer
by: Francois X. Claret, et al.
Published: (2012-06-01)

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
by: Davidson M, et al.
Published: (2016-11-01)

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
by: Rusz O, et al.
Published: (2018-09-01)

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
by: Fan Yang, et al.
Published: (2020-03-01)

Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin
by: Danielle D. Jandial, et al.
Published: (2017-03-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)

Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China
by: Zhou P, et al.
Published: (2016-04-01)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
by: Linehan AS, et al.
Published: (2021-02-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

Nature-Inspired Nanoparticles as Paclitaxel Targeted Carrier for the Treatment of HER2-Positive Breast Cancer
by: Celia Nieto, et al.
Published: (2021-05-01)

Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
by: Li X, et al.
Published: (2021-07-01)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01)

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
by: Iain R. Macpherson, et al.
Published: (2019-12-01)

Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
by: Wesam Abdel-Razaq, et al.
Published: (2019-01-01)

MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6
by: Xiangdong Lu, et al.
Published: (2017-12-01)